Imaging the norepinephrine transporter in neuroblastoma: A comparison of [18F]-MFBG and 123I-MIBG

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2182-2191

  Zhang, Hanwen ^a   Huang, Ruimin ^a   Cheung, Nai Kong V ^a   Guo, Hongfen ^a   Zanzonico, Pat B ^a   Thaler, Howard T ^a   Lewis, Jason S ^a   Blasberg, Ronald G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; METAFLUOROBENZYLGUANIDINE F 18; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; 3-FLUOROBENZYLGUANIDINE; FLUOROBENZENE; GUANIDINE DERIVATIVE; SLC6A2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL LEVEL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NEUROBLASTOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIOACTIVITY; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; COMPARATIVE STUDY; DIAGNOSTIC USE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

3-IODOBENZYLGUANIDINE; ANIMALS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FLUOROBENZENES; GUANIDINES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 84898985501     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1153     Document Type: Article

References (30)

1. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397-411.
2. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041-6.
3. Goodman M, Gurney J, Smith M, Olshan A. Sympathetic nervous system tumors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
4. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243-57.
5. Taggart DR, Han MM,Quach A, Groshen S, Ye W, Villablanca JG, et al., Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343-9.
6. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaineand antidepressant-sensitive human noradrenaline transporter. Nature 1991;350:350-4.
7. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging 2008;52:351-68.
8. Grunwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semi Nucl Med 2010;40:153-63.
9. Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging 2008;52:341-50.
10. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27: 298-303.
11. Dessner DA, DiPietro MA, Shulkin BL. MIBG detection of hepatic neuroblastoma: correlation with CT, US and surgical findings. Pediatr Radiol 1993;23:276-80.
12. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24.
13. Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011;38: 1648-58.
14. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005;46: 455-63.
15. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27: 289-97.
16. Sisson JC, Yanik GA. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors. Semi Nucl Med 2012;42:171-84.
17. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012;18:2740-53.
18. Jacobson AF, Deng H, Lombard J, Lessig HJ. Black RR, 123I- metaiodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010;95:2596-606.
19. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74.
20. Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[18F]fluoro-3-iodobenzyl) guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem 1994;37:3655-62.
21. Lee BC, Paik JY, Chi DY, Lee KH, Choe YS, Potential and practical adrenomedullary PET radiopharmaceuticals as an alternative to miodobenzylguanidine: m-(omega-[18F]fluoroalkyl)benzylguanidines. Bioconjug Chem 2004;15:104-11.
22. Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, Kagan M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging 2011;4:435-43.
23. Zhang H, Huang R, Pillarsetty N, Thorek DL, Vaidyanathan G, Serganova I, et al. Synthesis and evaluation of (18)F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging 2014;41:322-32.
24. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
25. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008;49: 1613-9.
26. Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endoc Relat Cancer 2009;16: 255-65.
27. Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003;51:1027-40.
28. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94:4757-67.
29. Gelfand MJ, Parisi MT, Treves ST. Pediatric nuclear medicine dose reduction W, pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 2011;52: 318-22.
30. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, et al. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys 2010;37: 4861-7.